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Introduction 
        Angioedema is a potentially lethal swelling of the 
interstitial space from extravasation of intravascular 
plasma (Wood, Choromanski, & Orlewicz, 2013). 
Angioedema may present in any medical setting with a 
broad range of severity. Angioedema is commonly seen 
in emergency departments and intensive care units. 
According to Barbara, Ronan, Maddox, & Warner 
(2013), “angioedema is of particular importance to 
anesthesiologists, as it may present at any point in the 
perioperative period and it may rapidly become life-
threatening if it involves airway compromise” (p. 335). 
Anesthesia professionals may also respond to airway 
management emergencies throughout the hospital 
setting and may treat angioedema secondary to 
anesthetics. Emergency providers and advanced 
practitioners should be able to recognize the signs and 
symptoms, differentiate between histaminergic and 
non-histaminergic, and provide emergent treatment of 
angioedema in all care settings.  
Signs and Symptoms 
• Dyspnea 
• Dysphagia 
• Odynophagia 
• Stridor 
• Hoarseness 
• Drooling 
• Tachypnea 
• Hypovolemic shock 
• Hypotension 
• Tachycardia 
• Urticaria (histaminergic only) 
• Abdominal pain (Bowel edema may present 
like an acute abdomen; avoid surgery.) 
• Vomiting (Hereditary Angioedema; HAE) 
• Weakness (HAE) 
• Face 
• Eyelids 
• Tongue 
• Oral cavity 
• Neck  
• Throat 
Location 
• Glottic 
structures 
• Extremitie
s 
• Trunk 
• Genitals 
• Bowel 
Classification 
        Primary angioedema may be classified as mast cell 
mediated (histaminergic) or bradykinin mediated (non-
histaminergic) (Bartal, Zeldetz, Stavi, & Barski, 2015). 
Angioedema can be caused by reactions to many 
different substances including drugs, food, and insect 
bites/stings (Barbara et al., 2012). The most common 
drugs associated with angioedema are angiotensin 
converting enzyme (ACE) inhibitors, ARBs, antibiotics, 
muscle relaxants, opioids, NSAIDS, and raidiocontrast 
agents (Barbara et al., 2012). Sonny, Avitsian, Hussain, 
& Elsharkawy (2015) note a 1.3% to 5.1% incidence of 
angioedema following infusion of recombinant tissue 
plasminogen activator (rtPA). Hereditary angioedema 
episodes can be triggered by stress trauma, estrogen, 
or surgery, especially dental surgery (Senaratne, 
Cottrell, & Prentice, 2012). Secondary angioedema may 
present as a symptom of anaphylaxis, “a sever life 
threatening generalized or systemic hypersensitivity 
reaction” (Dhami et al. 2013, p.169).  
      Histaminergic angioedema is an IgE 
mediated, type 1 hypersensitivity reaction 
that results in the degranulation of histamine 
from granulocytes, primarily mast cells. 
Histamine release causes localized 
vasodilation and increased vascular 
permeability resulting in the extravasation of 
intravascular plasma into the interstitial 
space causing swelling of the subcutaneous 
and submucosal tissues (Wood et al., 2013). 
Because the majority of angioedema cases 
are histaminergic reactions, first line 
medications for treatment of all types of 
angioedema include anti-histamines (H1 and 
H2 receptor blockers), corticosteroids to 
blunt the immune response, and epinephrine 
to inhibit mast cell degranulation (Moellman, 
Bernstein, & Lindsell, 2014). 
       Non-histaminergic angioedema is 
bradykinin mediated and can be due 
to hereditary deficiency or 
dysfunction of C1-inhibitor, or drugs 
including ACE inhibitors. Bradykinin 
is an inflammatory mediator that 
causes vasodilation, increased 
vascular permeability, nonvascular 
smooth muscle contraction, and 
oedema formation (Spyridonidou et 
al., 2010).  It should be noted that 
anti-histamines and corticosteroids 
are ineffective in the treatment of 
non-histaminergic angioedema, and 
epinephrine is only minimally 
effective (Moellman, et al. 2014).  
Pathophysiology 
Histamine vs. Bradykinin 
Airway Risk Assessment Tools 
        In 2001, Chiu, Newkirk, Davidson, 
Burningham, Krowiak, & Deeb (2001) 
classified patients with angioedema into 3 
risk categories for intubation based on the 
specific locations of facial, oral, and 
oropharyngeal swelling. Type 1 included 
facial and oral edema that excluded the floor 
of the mouth (0% intubated); type 2 
included oropharynx and/or floor of the 
mouth edema (21.4% intubated, 7.1% 
surgical airway), and type 3 included 
oropharyngeal edema including the 
supraglottic and glottic structures (33.3% 
intubated) (Chiu et al, 2001). This 
categorization system for patients with 
angioedema remains useful for airway risk 
assessment when airways are not acutely 
compromised and fiberoptic bronchoscopy is 
immediately available (Wood et al., 2013).  
        In 1999, Ishoo, Shah, Grillone, Stram, and 
Fuleihan proposed a staging criteria for 
angioedema: stage 1 facial rash, facial edema, 
and lip edema, stage 2 soft palate edema, 
stage 3 lingual edema, and stage 4 laryngeal 
edema. Stages 1 and 2 could be treated 
outpatient or as inpatient observational, while 
7% of stage 3 and 24% of stage 4 required 
artificial airways (Ishoo et al. 1999). Ishoo et 
al. (1999) found that voice changes, 
hoarseness, dyspnea, and stridor were the 
strongest predictors of the need for an 
artificial airway. Moellman et al. (2014) note 
that while the Ishoo criteria have been used 
for years to help decide whether to admit or 
discharge a patient, “these criteria have not 
yet been validated” (p. 473). While more 
information may be needed, the Ishoo criteria 
and study remain useful. 
Significance of Pathophysiology 
        Hereditary angioedema (HAE) is caused by an autosomal dominant defect in the C1-
INH gene that results in low levels of C1 esterase inhibitor (C1-INH) or ineffective C1-INH 
protein (Senaratne et al. 2012). C1-INH is a protein responsible for the inhibition of the 
complement inflammatory pathway and inhibition of B2 receptors in the kinin pathway 
(Senaratne et al. 2012). Without inhibition of the kinin pathway, bradykinin levels rise 
resulting in episodic angioedema. Rarely C1-INH may become deficient due to the 
development of autoantibodies or a lymphoproliferative disorder (Moellman et al., 2014).  
        Diagnosis of HAE is difficult in the acute setting, but HAE can be suspected if the 
patient’s family history indicates autosomal dominant penetrance. Moellman et al. (2014) 
recommends checking serum C4 and tryptase levels during acute episodes of suspected HAE 
to aid in diagnosis, but these values are rarely useful in the acute setting and provide the 
most utility to immunologists in follow-up appointments. Serum C1 inhibitor level and C1 
inhibitor activity level may be used in sub-acute setting (Senaratne et al. 2012). Plasma C1-
INH concentrates, B2 receptor antagonists (icatibant), and kallikrein receptor blockers 
(ecallantide) can be used to treat bradykinin-mediated angioedema in the acute setting 
(Moellman et al., 2014) or prophylactically in the preoperative and perioperative setting 
(Senaratne et al., 2012). 
        ACE inhibitor therapy can cause angioedema at any time, but most reactions occur 
within the first few weeks after initiation or dose changes (Chan & Soliman, 2015). 
Angiotensin converting enzyme (ACE, identical to Kinase II) is responsible for the 
breakdown of bradykinin at the B2 receptor on the cell membrane (Bartal et al. 2015). When 
ACE (Kinase II) is inhibited, bradykinin levels can progressively increase and cause 
angioedema. Discontinue the ACE inhibitor. Fresh frozen plasma administration has been 
successfully used to treat ACE inhibitor related angioedema presumably because plasma 
contains small amounts of Kinase II (ACE), which can breakdown excess bradykinin 
(Senaratne et al. 2012). More research needs to be completed on the potential benefit of 
administering plasma C1-INH concentrate, B2 receptor antagonist, or kallikrein receptor 
blockers in patients with ACE inhibitor induced angioedema (off-label use) (Moellman et al., 
2014) . However, small studies are emerging with promising results. Bartal, Zeldetz, Stavi, & 
Barski (2015) presented a case study that showed rapid resolution of ACE inhibitor induced, 
refractory, life-threatening laryngeal edema after a single subcutaneous icatibant (B2 
antagonist) injection. Other case studies show similar results (Bartal et al. 2015). 
Characteristics of Edema 
• Non-pitting 
• Non-gravity dependent 
• Often asymmetric 
• Transient 
• Self-Limiting 
Nursing Implications 
• Assess the extent of tissue 
involvement 
• Apply treatment algorithms 
• Ongoing assessment of airway, 
vital signs, symptom progression, 
and response to treatment 
• Continuous cardiac monitor 
• Continuous pulse-ox 
• Fluid resuscitation 
• Medical & family history 
Treatment 
        It is important to differentiate between histaminergic 
angioedema, non-histaminergic angioedema (bradykinin), 
and anaphylactic reactions. For all etiologies, treatment can 
begin with anti-histamines and corticosteroids, and include 
epinephrine in the presence of stridor, new hoarseness of 
voice, or life threatening reaction (Moellman, Bernstein, & 
Lindsell, 2014). Although Moellman et al. (2014) note that 
“the only potential acute treatment currently readily available 
for the treatment of ACE-induced or other bradykinin-
mediated angioedema in the ED is fresh-frozen plasma (FFP)” 
(p. 473), approved plasma C1-INH protein concentrates, 
kallikrein inhibitors (Ecallantide), and bradykinin 2-receptor 
blockers (Icatibant) may be available at some facilities when 
patients are suspected to have hereditary angioedema and 
can be considered for other non-histaminergic (bradykinin 
induced) angioedema (Moellman et al. 2014).  
The tongue swelling of a patient with ACE inhibitor induced angioedema, before (A) and 
30 minutes after (B) treatment with 30mg SubQ icatibant, Source: Bartal, Zeldetz, Stavi, & 
Barski, p. 479e2 (2015). 
A B 
62% 34% 1% 
Histamine ACE inhibitor
(Bradykinin)
C1EI
(Bradykinin)
  
Estimated Classification in Primary Angioedema  
Cases Presenting to the Hospital 
Conclusion 
Healthcare providers need to be able to promptly recognize the clinical manifestations of 
angioedema because airway involvement and hypovolemic shock can be life-threatening. Airway 
management is of primary importance. Most angioedema reactions are histaminergic. Bradykinin-
mediated angioedema is becoming more common with increased use of ACE inhibitors. Hereditary 
angioedema should be recognized with a detailed family history, and prophylactic treatment prior to 
surgical procedures is recommended (Moellman et al. 2014). Patients presenting with angioedema 
rely on healthcare providers to possess the clinical skill and medical expertise to prevent adverse 
outcomes. 
 
